Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 720

1.

IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.

Rose A, von Spee-Mayer C, Kloke L, Wu K, Kühl A, Enghard P, Burmester GR, Riemekasten G, Humrich JY.

Cells. 2019 Oct 11;8(10). pii: E1234. doi: 10.3390/cells8101234.

2.

Fluoreszenzoptische Bildgebung zum Nachweis einer möglichen Psoriasisarthritis im Vergleich zum muskuloskelettalen Ultraschall.

Erdmann-Keding M, Ohrndorf S, Werner SG, Glimm AM, Burmester GR, Kokolakis G, Zuberbier T, Sterry W, Backhaus M, Philipp S.

J Dtsch Dermatol Ges. 2019 Sep;17(9):913-922. doi: 10.1111/ddg.13931_g. German.

PMID:
31538745
3.

Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound.

Erdmann-Keding M, Ohrndorf S, Werner SG, Glimm AM, Burmester GR, Kokolakis G, Zuberbier T, Sterry W, Backhaus M, Philipp S.

J Dtsch Dermatol Ges. 2019 Sep;17(9):913-921. doi: 10.1111/ddg.13931.

PMID:
31538737
4.

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period.

Glimm AM, Sprenger LI, Haugen IK, Mansmann U, Hermann S, Häupl T, Hoff P, Burmester GR, Backhaus M, Le L, Ohrndorf S.

Arthritis Res Ther. 2019 Sep 18;21(1):209. doi: 10.1186/s13075-019-1989-5.

5.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
6.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
7.

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.

Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR.

RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019.

8.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR.

Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265. [Epub ahead of print]

PMID:
31312844
9.

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.

Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake TRDJ.

Ann Rheum Dis. 2019 Jun 22. pii: annrheumdis-2019-215694. doi: 10.1136/annrheumdis-2019-215694. [Epub ahead of print]

PMID:
31229952
10.

[Treat to target: therapeutic aims/prognosis parameters].

Schneider M, Burmester GR.

Z Rheumatol. 2019 Jun;78(5):394-395. doi: 10.1007/s00393-019-0638-3. German. No abstract available.

PMID:
31172315
11.

Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).

Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP.

Clin Exp Rheumatol. 2019 Apr 16. [Epub ahead of print]

PMID:
31025930
12.

[Tight control-Demand for short term control of rheumatoid arthritis].

Schneider M, Burmester GR.

Z Rheumatol. 2019 Jun;78(5):404-412. doi: 10.1007/s00393-019-0631-x. Review. German.

PMID:
31001653
13.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

14.

Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis.

Friedrich S, Lüders S, Glimm AM, Werner SG, Schmittat G, Burmester GR, Backhaus M, Riemekasten G, Ohrndorf S.

Arthritis Res Ther. 2019 Apr 15;21(1):96. doi: 10.1186/s13075-019-1875-1.

15.

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.

Braun J, Baraliakos X, Kiltz U, Krüger K, Burmester GR, Wassenberg S, Thomas MH.

J Rheumatol. 2019 Mar 15. pii: jrheum.181040. doi: 10.3899/jrheum.181040. [Epub ahead of print]

16.

Do musculoskeletal ultrasound and magnetic resonance imaging identify synovitis and tenosynovitis at the same joints and tendons? A comparative study in early inflammatory arthritis and clinically suspect arthralgia.

Ohrndorf S, Boer AC, Boeters DM, Ten Brinck RM, Burmester GR, Kortekaas MC, van der Helm-van Mil AHM.

Arthritis Res Ther. 2019 Feb 14;21(1):59. doi: 10.1186/s13075-019-1824-z.

17.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

18.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
19.

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.

Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T.

Arthritis Rheumatol. 2019 Jul;71(7):1042-1055. doi: 10.1002/art.40841. Epub 2019 May 25.

20.

[Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population].

Freier D, Englbrecht M, Höhne-Zimmer V, Detert J, Burmester GR.

Z Rheumatol. 2018 Dec 3. doi: 10.1007/s00393-018-0571-x. [Epub ahead of print] German.

PMID:
30511171
21.

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?

Avci AB, Feist E, Burmester GR.

BioDrugs. 2018 Dec;32(6):531-546. doi: 10.1007/s40259-018-0320-3.

PMID:
30488231
22.

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.

Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH.

Rheumatol Int. 2019 Jan;39(1):131-140. doi: 10.1007/s00296-018-4180-4. Epub 2018 Nov 10.

23.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

24.

Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.

Baganz L, Richter A, Albrecht K, Schneider M, Burmester GR, Zink A, Strangfeld A.

Semin Arthritis Rheum. 2019 Jun;48(6):976-982. doi: 10.1016/j.semarthrit.2018.09.003. Epub 2018 Sep 17.

25.

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis.

Diekhoff T, Ulas ST, Poddubnyy D, Schneider U, Hermann S, Biesen R, Burmester GR, Hamm B, Hermann KG.

Ann Rheum Dis. 2019 Jan;78(1):31-35. doi: 10.1136/annrheumdis-2018-213904. Epub 2018 Sep 29.

26.

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):367-378. doi: 10.1002/acr.23738. Epub 2019 Feb 12.

27.

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells.

Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, Ohrndorf S, Pfeiffenberger M, Röhner E, Matziolis G, Burmester GR, Buttgereit F, Hoff P.

Int J Mol Sci. 2018 Aug 7;19(8). pii: E2312. doi: 10.3390/ijms19082312.

28.

Observational study and brief analysis of diagnostic criteria in relapsing polychondritis.

Rose T, Schneider U, Bertolo M, Klotsche J, Casteleyn V, Biesen R, Burmester GR, Hiepe F.

Rheumatol Int. 2018 Nov;38(11):2095-2101. doi: 10.1007/s00296-018-4121-2. Epub 2018 Aug 6.

PMID:
30084004
29.

Response to: 'Digital health: a new dimension in rheumatology patient care' by Kataria and Ravindran.

Burmester GR.

Ann Rheum Dis. 2019 Oct;78(10):e104. doi: 10.1136/annrheumdis-2018-214154. Epub 2018 Aug 2. No abstract available.

PMID:
30072487
30.

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F.

Eur J Immunol. 2018 Sep;48(9):1573-1579. doi: 10.1002/eji.201847492. Epub 2018 Jul 30.

31.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

32.

[Tips and tricks in court-Practical experience from a medical viewpoint].

Burmester GR.

Z Rheumatol. 2018 Sep;77(7):587-592. doi: 10.1007/s00393-018-0490-x. Review. German.

PMID:
29947948
33.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

34.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669
35.
36.

Rheumatology 4.0: big data, wearables and diagnosis by computer.

Burmester GR.

Ann Rheum Dis. 2018 Jul;77(7):963-965. doi: 10.1136/annrheumdis-2017-212888. Epub 2018 May 25. No abstract available.

37.

Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss.

Parsons CM, Judge A, Leyland K, Bruyère O, Petit Dop F, Chapurlat R, Reginster JY, Edwards MH, Dennison EM, Cooper C, Inskip H; SEKOIA Study Group.

Arthritis Care Res (Hoboken). 2019 Feb;71(2):300-307. doi: 10.1002/acr.23596.

38.

[Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark].

Häupl T, Skapenko A, Hoppe B, Skriner K, Burkhardt H, Poddubnyy D, Ohrndorf S, Sewerin P, Mansmann U, Stuhlmüller B, Schulze-Koops H, Burmester GR.

Z Rheumatol. 2018 May;77(Suppl 1):16-23. doi: 10.1007/s00393-018-0458-x. Review. German.

PMID:
29691690
39.

[Big data-also relevant in rheumatology?]

Burmester GR, Häupl T.

Z Rheumatol. 2018 Apr;77(3):192-194. doi: 10.1007/s00393-018-0437-2. German. No abstract available.

PMID:
29619762
40.

Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.

Weigold F, Günther J, Pfeiffenberger M, Cabral-Marques O, Siegert E, Dragun D, Philippe A, Regensburger AK, Recke A, Yu X, Petersen F, Catar R, Biesen R, Hiepe F, Burmester GR, Heidecke H, Riemekasten G.

Arthritis Res Ther. 2018 Mar 22;20(1):52. doi: 10.1186/s13075-018-1545-8.

41.

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.

Schwedler C, Häupl T, Kalus U, Blanchard V, Burmester GR, Poddubnyy D, Hoppe B.

Arthritis Res Ther. 2018 Mar 14;20(1):44. doi: 10.1186/s13075-018-1540-0.

42.

Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13.

43.

Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Ann Rheum Dis. 2018 Jun;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565. Epub 2018 Mar 13.

PMID:
29525777
45.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
46.

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM.

Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.

PMID:
29402521
47.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

48.

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J.

Ann Rheum Dis. 2018 Apr;77(4):476-479. doi: 10.1136/annrheumdis-2017-212256. Epub 2018 Jan 4.

PMID:
29301783
49.

Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint.

Smiljanovic B, Radzikowska A, Kuca-Warnawin E, Kurowska W, Grün JR, Stuhlmüller B, Bonin M, Schulte-Wrede U, Sörensen T, Kyogoku C, Bruns A, Hermann S, Ohrndorf S, Aupperle K, Backhaus M, Burmester GR, Radbruch A, Grützkau A, Maslinski W, Häupl T.

Ann Rheum Dis. 2018 Feb;77(2):300-308. doi: 10.1136/annrheumdis-2017-211649. Epub 2017 Nov 30.

50.

Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.

Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R.

J Rheumatol. 2018 Feb;45(2):177-187. doi: 10.3899/jrheum.170486. Epub 2017 Nov 15.

Supplemental Content

Loading ...
Support Center